Perspective Therapeutics reports 39% ORR in Cohort 2 of [212Pb]VMT-α-NET trial; safety cleared at 6.0 mCi

Perspective Therapeutics, Inc.

Updated interim data from Phase 1/2a trial of [212Pb]VMT-α-NET in SSTR2-expressing NETs at ASCO-GI.
Objective response rate of 39% (9/23) in Cohort 2 per RECIST v1.1; 8 confirmed, 1 pending.
76% (19/25) of evaluable patients without progression and alive; deepening of best response seen in 7 patients.
DLT assessment completed for Cohort 3 (6.0 mCi); cleared to enroll more; one additional patient already treated.
No DLTs, treatment-related discontinuations, or serious renal complications across 56 patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.